Skipping hormone therapy for low-risk breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether women with very low-risk, early-stage breast cancer can safely skip hormone therapy after surgery. It is designed for women who are 60 or older and whose cancer shows no spread to lymph nodes and has favorable biology.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 or older and no longer have menstrual periods (either from natural menopause or ovary removal).
- Your tumor was 1 cm or smaller, slow-growing (low grade), and the cancer type is ductal, tubular, or mucinous (not lobular).
- No cancer in your lymph nodes (confirmed by exam or imaging like ultrasound).
- Your tumor is hormone receptor positive (ER 50%+ and PR 20%+, Ki67 low, HER2 negative).
- You had surgery (lumpectomy or mastectomy) with clear edges. If you had a lumpectomy, you must get or plan to get radiation to the breast.
- You have not had any hormone therapy, chemotherapy, or other cancer treatment for this breast cancer yet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
This trial tests whether older women with very low-risk, hormone-positive breast cancer can safely skip endocrine therapy (hormone-blocking pills) and radiation after lumpectomy. It aims to maintain quality of life while keeping cancer from coming back.
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This Phase 2 trial tests whether some people with early HER2-positive breast cancer can safely skip surgery and sentinel lymph node removal after finishing standard hormone-free anti-HER2 chemotherapy and getting a complete response. It may reduce treatment-related side effects if you meet strict low-risk criteria.
This study is looking at whether it is safe for younger women who have had surgery for a very early-stage, low-risk breast condition called DCIS to skip radiation therapy. The goal is to see if they can avoid the side effects of radiation without the cancer coming back.
Hear when a new Breast Cancer (Early Breast Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.